摘要
随着透析质量的提高,透析龄的延长,透析慢性并发症引起关注。慢性肾脏病矿物质、骨代谢异常(CKD-MBD)是长期透析患者的严重并发症之一,影响透析患者的生活质量,更增加透析患者的死亡风险。高磷血症是CKD-MBD的始动因素,新型降磷药物碳酸司维拉姆,可有效控制血磷水平,提高透析患者的生存质量,不良反应较少,并有降血磷之外的益处,本文综述碳酸司维拉姆治疗CKD-MBD患者的临床应用研究进展。
Chronic kidney disease-mineral and bone disorder （CKD-MBD） is one of the serious complications of long-term dialysis patients, which not only affects the life quality of dialysis patients, but also increases the death risk of dialysis patients. The existing research supports that the hypcrphosphatemia is the initiating factor of CKD-MBD. Effective control of serum phosphorus level can improve patients＇ life quality and their prognosis. Sevelamer carbonate is a new type of phosphate binder, which has the exact effect and less side effects compared with the calcium-based phosphate binders. It has been proved to have other more benefits than reducing phosphorus. This paper reviews the clinical application of sevelamer carbonate in the treatment of CKD-MBD.
作者
郭姗姗
王玉柱
GUO Shan-shan,WANG Yu-zhu(Department of Nephrology, Beijing Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beoing 100080, Chin)
出处
《世界临床药物》
CAS
2018年第3期I0002-I0006,共5页
World Clinical Drug
关键词
碳酸司维拉姆
高磷血症
透析
sevelamer carbonate
hyperphosphatemia
dialysis
